Aptimmune Biologics specializes in the development and application of prophylactic measures against viral diseases of swine. The current focus is bringing into the market effective prophylaxis against Porcine Reproductive and Respiratory Syndrome (PRRS) virus. Aptimmune utilizes novel technologies to create effective vaccines against PRRSV such as the proprietary pig alveolar macrophage cell line ZMAC. Dr. Zuckermann founded Aptimmune Biologics in 2010 to commercialize vaccine technologies. Dr. Zuckermann is currently a Professor of Immunology at the University of Illinois.
EnterpriseWorks Tenure: 2010-2018
News & Milestones
Aptimmune Biologics Now:
After graduating from EnterpriseWorks in 2018, Aptimmune Biologics was acquired by Kemin Industries, and the two companies announced their partnership in the global vaccine industry.